As Roivant’s uni­corn val­u­a­tion swells to $7B, Ra­maswamy scoops up $200M to back a new burst of star­tups

Vivek Ra­maswamy nev­er hid his am­bi­tions in swift­ly build­ing Roivant in­to a glob­al bio­phar­ma play­er. But now he’s of­fer­ing some new de­tails about just how suc­cess­ful he’s been in grow­ing the com­pa­ny’s mega-block­buster uni­corn val­u­a­tion while con­tin­u­ing to bring in sig­nif­i­cant new amounts of cash to keep adding to the num­ber of com­pa­nies and drugs un­der his watch. 

To­day Roivant is un­veil­ing a $200 mil­lion raise for the com­pa­ny — bring­ing the to­tal to more than $3 bil­lion from all sources. And the biotech um­brel­la group — which op­er­ates a dozen pub­lic and pri­vate op­er­a­tions — says this new mon­ey came in with a val­u­a­tion of $7 bil­lion for Roivant — which a com­pa­ny spokesman says is up from $5.6 bil­lion from its last raise in 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER